Herpes Cure Research in 2026: Vaccines, Gene Editing and New Drugs

Editorial note: This page is no longer updated. For the latest on pritelivir's FDA review, Gilead's weekly pill and gene editing trials, see our herpes cure research update for 2027.

HSV-1 and HSV-2 together infect more than 4 billion people. WHO estimates that about 3.8 billion people under 50 carry HSV-1 and roughly 520 million people aged 15 to 49 carry HSV-2. No vaccine or cure has been approved, and none will be in 2026.

The research is moving, but not evenly. In 2026 the real progress is in new antiviral drugs: pritelivir is awaiting an FDA decision, and Gilead is preparing a Phase 2 trial of a once-weekly pill. Vaccines had a hard two years, with Moderna and GSK both pulling out. Gene editing, the only approach that could remove the virus completely, is still preparing for its first genital herpes trial.

This page covers the whole picture and why each approach takes as long as it does. For a candidate-by-candidate list of vaccines, see our 2027 herpes vaccine tracker.

Herpes is hard to cure because it hides inside nerve cells

After the first infection, HSV travels up nerve fibers and settles in clusters of nerve cells called ganglia. There it goes quiet, a state called latency. The viral DNA sits in the nucleus of the neuron and makes almost no proteins, so the immune system has nothing to target.

Current antivirals such as acyclovir and valacyclovir only work on virus that is actively copying itself. They shorten outbreaks and reduce shedding, but they cannot touch the dormant virus. A cure would need to either destroy that latent DNA or keep it permanently switched off.

The virus also fights back against the immune system. HSV reduces the markers on infected cells that T-cells use to spot them, blocks interferon signaling and produces proteins that disable antibodies and complement. That is why a vaccine that only produces antibodies tends to fail.

Past vaccines show how hard this is. GSK's Herpevac, a gD2 protein vaccine, was tested in more than 8,000 women. Published in 2012, it protected about 58% of women against genital disease caused by HSV-1 but had no significant effect against HSV-2. Genocea's GEN-003, a therapeutic vaccine, reduced shedding modestly in Phase 2 but was shelved in 2017 when the company couldn't fund Phase 3.

Each vaccine type has trade-offs. Live-attenuated vaccines produce stronger T-cell and mucosal immunity, but regulators need extensive proof that they are safe for people with weak immune systems. Protein vaccines are very safe but have produced weak T-cell responses. mRNA vaccines sit in between and are the newest approach.

Vaccine research lost two major players in two years

In September 2024, GSK ended its therapeutic vaccine, GSK3943104, after the Phase 2 trial in people with recurrent genital herpes did not meet its efficacy objective.

In November 2025, Moderna announced it would not take its therapeutic mRNA vaccine, mRNA-1608, into Phase 3. This was a budget decision. Interim Phase 1/2 results in about 300 people with recurrent HSV-2 showed no major safety concerns, higher antibody levels and early trends toward fewer recurrences.

BioNTech's BNT163 is now the only herpes vaccine in clinical trials at a large drug company. It is a preventive mRNA vaccine encoding three HSV-2 proteins (gC, gD and gE), developed with the University of Pennsylvania. The Phase 1 trial, which began in December 2022, found it well tolerated and able to produce neutralizing antibodies.

It is due to finish in October 2026. BioNTech has not announced an efficacy trial.

Rational Vaccines is preparing a Phase 1 trial of RVx201, a live-attenuated HSV-2 vaccine, in the UK. It started collecting volunteer details in February 2026.

Sanofi's HSV529, a replication-defective vaccine, was discontinued in 2022. It still appears in animal comparisons, but there is no active human program. Other live-attenuated strains, such as ΔgD-2 and gD27, have protected animals well but are not in human trials.

New antivirals are the nearest real advance

Helicase-primase inhibitors block a viral enzyme that current drugs don't touch. They work against strains resistant to acyclovir and, because some stay in the body for days, they may allow weekly dosing.

Pritelivir (AiCuris) met its Phase 3 goal in immunocompromised patients with herpes infections that weren't healing: 82.4% healed completely, versus 42.0% on other treatments. The FDA granted Priority Review in April 2026, with a decision expected in the fourth quarter of 2026. It would be the first new herpes drug in over 20 years, initially for this narrow group. See our pritelivir guide.

GS-1179 (Gilead, formerly Assembly Bio's ABI-1179) is a once-weekly pill. In a 29-day Phase 1b study, a 50 mg weekly dose cut HSV-2 shedding by 98% versus placebo. Gilead licensed it in December 2025 and expects to start Phase 2 by the end of 2026. More in our weekly herpes pill update.

Amenamevir, another drug in this class, is already approved in Japan for shingles and recurrent cold sores, which shows the class is safe and effective in people.

Gene editing is the only approach aiming for a true cure

Gene editing tries to cut the dormant viral DNA inside neurons so it can never reactivate.

At Fred Hutchinson Cancer Center, Dr. Keith Jerome's team uses meganucleases delivered by adeno-associated virus (AAV). A 2024 study using a single vector and a single enzyme that cuts the viral DNA in two places removed 90% or more of latent HSV-1 in mice, with fewer side effects on the liver and nerves than earlier versions.

The team has said it hopes to start human trials around 2026 or 2027. None has been registered yet.

In China, BDgene's BD111 uses CRISPR delivered in virus-like particles to target HSV-1 in the cornea, where it causes herpetic stromal keratitis, a leading infectious cause of blindness. Early human results were published in 2023, and a 40-patient Phase 2a trial is due to complete in December 2026.

The main hurdles are delivering the editor to every infected ganglion, avoiding cuts in human DNA, and proving long-term safety in nerve tissue.

Approval takes years even when a trial succeeds

A preventive herpes vaccine needs a Phase 3 trial with thousands of participants followed for one to two years, because researchers have to wait for enough new infections to compare groups. Recruiting, following and analyzing such a trial takes two to four years.

A therapeutic vaccine or a new antiviral can use smaller trials, since outbreaks and viral shedding can be measured in people who are already infected. That is one reason drugs are moving faster than preventive vaccines.

After a successful Phase 3, standard FDA review takes about 10 to 12 months, or 6 to 8 months with Priority Review. Manufacturing scale-up and supply add more time.

For a sense of scale, HPV vaccines took about 15 years from discovery to approval, and GSK's shingles vaccine Shingrix took about two decades. mRNA COVID-19 vaccines were fast because of unprecedented funding, a global emergency and huge numbers of infections during trials. None of those conditions applies to herpes.

Fast-track programs can shorten the wait

The FDA has several programs that speed up promising treatments. Pritelivir used most of them, receiving Fast Track, Breakthrough Therapy and Priority Review designations.

A herpes vaccine or drug could move faster if:

• Phase 2 shows a large, clear reduction in outbreaks or shedding
• a bigger company or public funder takes on an abandoned candidate such as mRNA-1608
• regulators accept viral shedding as a surrogate endpoint, which would allow smaller and shorter trials
• combination approaches, such as a vaccine plus a long-acting antiviral, show added benefit

Timelines get longer if:

• Phase 2 results are modest and the trial has to be redesigned
• unexpected safety signals appear, especially for live-attenuated vaccines or gene editing
• companies cut funding, as Moderna did
• trials struggle to recruit and keep participants over long follow-up periods

A realistic timeline puts new options around 2030

Based on where each program stands in October 2026:

• Pritelivir: possible FDA approval in late 2026, for drug-resistant herpes in immunocompromised patients
• Once-weekly pill (GS-1179): Phase 2 starting late 2026, possible approval around 2030 or later
• Preventive vaccine (BNT163): efficacy trial not yet announced, approval unlikely before 2030 to 2032
• Gene editing cure: first genital herpes trials possibly 2027, approval likely well into the 2030s

Many people with herpes have seen "cure by next year" headlines for decades. The candidates above are real, but each still has to pass trials that have stopped earlier efforts.

In the meantime, existing tools work. Daily suppressive antivirals cut outbreaks by 70% to 80% and reduce transmission to partners. Condoms, avoiding sex during outbreaks and disclosure further lower the risk. Many people also manage triggers with sleep, stress control and natural approaches to managing outbreaks.